Exosomal Thomsen–Friedenreich Glycoantigen as a Sensitive and Specific Biomarker for Colon, Ovarian and Prostate Cancer Diagnosis
Cancers · 21.11.2025 · 17 (23) · 3729
DOI: 10.3390/cancers17233729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 21.11.2025. Verfasst von Yafei Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, U.S. National Science Foundation, National Cancer Institute (NCI) of the National Institutes of Health.
Abstract (Originalsprache)
Background/Objectives: The screening and diagnosis of colon, ovarian, and prostate cancers are challenged by invasive procedures and lack of effective screening tests. To address these challenges, we developed an exosome-based liquid biopsy assay that utilized a new exosomal biomarker, α-linked Thomsen–Friedenreich glycoantigen (TF-Ag-α, Galβ1-3GalNAc-α). This assay provides a minimally invasive method with high sensitivity and specificity for the screening and diagnosis of colon, ovarian and prostate cancers.
Methods
Exosomal TF-Ag-α levels in 10 μL serum samples were measured using a compact, surface plasmon resonance-based biosensor developed to facilitate clinical translation. The diagnostic performance of exosomal TF-Ag-α was initially evaluated in a training set consisting of normal controls (n = 80) and cancer patients (n = 120, 40 for prostate, 40 for colon, and 40 for ovarian cancer), and then validated in an independent test set including normal controls (n = 29) and cancer patients (n = 60, 20 for each cancer type). Receiver operating characteristic (ROC) analysis was performed to assess diagnostic sensitivity, specificity and area under the curve (AUC) of exosomal TF-Ag-α.
Results
Serum samples from cancer patients showed significantly elevated levels of exosomal TF-Ag-α compared with normal controls. Exosomal TF-Ag-α distinguished all cancer patients from normal controls with a sensitivity of 99.2%, specificity of 100% and an overall accuracy of 99.5% at a cutoff value of 0.406.
Conclusions
These findings demonstrated the clinical translational promise of exosomal TF-Ag-α as a liquid biopsy biomarker for the detection of colon, ovarian and prostate cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
- Department of Electrical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
- For-Robin, Inc., Buffalo, NY 14221, USA.
Förderung
- NCI NIH HHS
- U.S. National Science Foundation
- National Cancer Institute (NCI) of the National Institutes of Health
- National Science Foundation
Zitieren
APA
Su, Y., Qi, M., Vasini, S., Reid, M. E., Rittenhouse-Olson, K., Dy, G. K., & Wu, Y. (2025). Exosomal Thomsen–Friedenreich Glycoantigen as a Sensitive and Specific Biomarker for Colon, Ovarian and Prostate Cancer Diagnosis. Cancers, 17(23), 3729. https://doi.org/10.3390/cancers17233729
Vancouver
Su Y, Qi M, Vasini S, Reid ME, Rittenhouse-Olson K, Dy GK, et al. Exosomal Thomsen–Friedenreich Glycoantigen as a Sensitive and Specific Biomarker for Colon, Ovarian and Prostate Cancer Diagnosis. Cancers. 2025;17(23):3729. doi:10.3390/cancers17233729
BibTeX
@article{Su2025,
author = {Su, Yafei and Qi, Man and Vasini, Shoaib and Reid, Mary E and Rittenhouse-Olson, Kate and Dy, Grace K and Wu, Yun},
title = {Exosomal Thomsen–Friedenreich Glycoantigen as a Sensitive and Specific Biomarker for Colon, Ovarian and Prostate Cancer Diagnosis},
journal = {Cancers},
year = {2025},
volume = {17},
number = {23},
pages = {3729},
doi = {10.3390/cancers17233729}
}
EUVIMED